Telomir Pharmaceuticals, Inc

Study used cell lines obtained from the Progeria Research Foundation to evaluate Telomir-1's effects on key drivers of accelerated aging

Treatment reversed tremors, ataxia, anxiety-like behavior, liver and kidney pathology damage, reduced copper accumulation, normalized ALT, AST, and bilirubin levels, and improved survival.

Building on previous data in Werner syndrome, showing Telomir-1 reset the epigenetic clock, extended telomere length, restored gene expression, reversed muscle loss, and rescued survival-alongside data in Age Related Macular Degeneration (AMD) demonstrating retinal regeneration and restored vision-the drug continues to show broad regenerative potential across rare genetic degenerative diseases

Treatment restored gene control, extended telomere length beyond healthy levels, reversed muscle and weight loss, reduced oxidative stress, and resulted in 100% survival - highlighting Telomir-1's potential to reverse key hallmarks of aging

Company to meet with prospective partners as it accelerates toward IND submission for Telomir-1, with plans to begin human dosing in the first half of 2026

A unique oral drug candidate that is shown to restore vision and regenerate the retina in an animal model, addressing a major unmet need in ocular therapeutics

Investment from largest shareholder strengthens balance sheet, signals insider conviction, and funds Telomir-1's upcoming IND submission for a rare disease indication

Antimicrobial resistance is recognized as one of the top global public health threats, and Telomir-Ag2 strengthens Telomir's pipeline with a differentiated candidate designed to address this urgent and expanding crisis

New Study Confirms Telomir-1 Also Reverses Oxidative Stress, Preserves Cellular Integrity, and Prevents Cell Death by Protecting Mitochondria-The Cell's Power Source and Gatekeeper of Life and Death

Oxidative stress drives aging and is a key factor in diseases like Alzheimer's, Age-related Macular Degeneration (AMD), cardiovascular diseases, cancer, and diabetes. It also plays a critical role in the progression of viral infections, such as avian influenza (bird flu), by exacerbating inflammation and cellular damage. Directly addressing oxidative stress and its consequences is essential to treating the underlying causes of these conditions and mitigating the severity of viral outbreaks.

Transaction follows a $5 million non-dilutive credit line from the same trusted partner, further reinforcing Telomir's financial strength and growth potential.

Building on preclinical success demonstrating age reversal, longevity, and increased healthspan, Telomir-1 appears to address insulin resistance at its root, achieving reversal to near pre-diabetic levels